Denise D’Andrea

1.1k total citations
29 papers, 862 citations indexed

About

Denise D’Andrea is a scholar working on Surgery, Oncology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Denise D’Andrea has authored 29 papers receiving a total of 862 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Surgery, 7 papers in Oncology and 7 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Denise D’Andrea's work include Lipoproteins and Cardiovascular Health (9 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (7 papers) and Antiplatelet Therapy and Cardiovascular Diseases (4 papers). Denise D’Andrea is often cited by papers focused on Lipoproteins and Cardiovascular Health (9 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (7 papers) and Antiplatelet Therapy and Cardiovascular Diseases (4 papers). Denise D’Andrea collaborates with scholars based in United States, Australia and Netherlands. Denise D’Andrea's co-authors include Samuel D. Wright, Andreas Gille, Charles L. Shear, Rachael Easton, Thomas R. Kleyman, Brigitte Coupaye-Gerard, Michael P. Madaio, Mary H. Foster, Mona Darwish and John H. Alexander and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of Clinical Oncology.

In The Last Decade

Denise D’Andrea

26 papers receiving 841 citations

Peers

Countries citing papers authored by Denise D’Andrea

Since Specialization

Citations

This map shows the geographic impact of Denise D’Andrea's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Denise D’Andrea with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Denise D’Andrea more than expected).

Fields of papers citing papers by Denise D’Andrea

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Denise D’Andrea. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Denise D’Andrea. The network helps show where Denise D’Andrea may publish in the future.

Co-authorship network of co-authors of Denise D’Andrea

This figure shows the co-authorship network connecting the top 25 collaborators of Denise D’Andrea. A scholar is included among the top collaborators of Denise D’Andrea based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Denise D’Andrea. Denise D’Andrea is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast 2025 ·Oncology and Therapy ·Balázs Halmos, (unknown), (unknown), Wade T. Iams, Xiuning Le, (unknown), (unknown), Luis E. Raez, Jonathan W. Riess, Joshua K. Sabari, (unknown), (unknown), Yichuan Xia, (unknown), Denise D’Andrea, (unknown), Andrew L. Johnson, Melissa L. Johnson	0
2	Infusion-Related Reaction Management With Amivantamab for EGFR Exon 20 Insertion Mutation NSCLC: A Practical Guide for Advanced Practitioners 2024 ·Journal of the Advanced Practitioner in Oncology ·(unknown), Whitney E. Lewis, (unknown), Amitabha Bhaumik, Denise D’Andrea, Andrew L. Johnson	0
3	Cutaneous Toxicities With Amivantamab for Non-Small Cell Lung Cancer: A Practical Guide and Best Practices 2024 ·Clinical journal of oncology nursing ·(unknown), Kaiwen Wang, (unknown), (unknown), Denise D’Andrea, Catherine A. Shu, (unknown), Stephanie M. Gallitano	1
4	Healthcare resource use (HRU) in men with metastatic castration sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT) only or no treatment in the United States (US). 2020 ·Journal of Clinical Oncology ·Xuehua Ke, Marie‐Hélène Lafeuille, (unknown), (unknown), Peter Francis, Denise D’Andrea, Charles J. Ryan, Stephen J. Freedland	2
5	Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study 2018 ·Journal of Thrombosis and Thrombolysis ·Paul A. Gurbel, Udaya S. Tantry, Denise D’Andrea, (unknown), John H. Alexander, Kevin P. Bliden, Samuel D. Wright, Pierluigi Tricoci	13
6	Abstract 16500: CSL112 Restores Cholesterol Efflux in Patients Immediately After Acute Myocardial Infarction 2017 ·Circulation ·Andreas Gille, Samuel D. Wright, Michael A. Tortorici, Danielle Duffy, (unknown), Megan K. Yee, Lawrence I. Deckelbaum, Denise D’Andrea, C. Michael Gibson	3
7	Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction 2016 ·American Heart Journal ·C. Michael Gibson, Serge Korjian, Pierluigi Tricoci, Yazan Daaboul, John H. Alexander, Philippe Gabríel Steg, A. Michael Lincoff, John J.P. Kastelein, Roxana Mehran, Denise D’Andrea, Béla Merkely, Maciej Zarębiński, (unknown), Robert A. Harrington	25
8	Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction 2016 ·Circulation ·C. Michael Gibson, Serge Korjian, Pierluigi Tricoci, Yazan Daaboul, Megan K. Yee, Purva Jain, John H. Alexander, Philippe Gabríel Steg, A. Michael Lincoff, John J.P. Kastelein, Roxana Mehran, Denise D’Andrea, Lawrence I. Deckelbaum, Béla Merkely, Maciej Zarębiński, Ton Oude Ophuis, Robert A. Harrington	144
9	Infusion of Reconstituted High‐Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial 2015 ·Journal of the American Heart Association ·Pierluigi Tricoci, Denise D’Andrea, Paul A. Gurbel, Zhenling Yao, Marina Cuchel, (unknown), Robert J. Schott, Robert Weiss, Michael A. Blazing, Louis Cannon, Alison Bailey, Dominick J. Angiolillo, Andreas Gille, Charles L. Shear, Samuel D. Wright, John H. Alexander	95
10	Abstract 15780: CSL112, A Novel Formulation of Human Apolipoprotein A-I, Dramatically Increases Cholesterol Efflux Capacity in Patients With Stable Atherothrombotic Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study 2013 ·Circulation ·Andreas Gille, Denise D’Andrea, (unknown), Pierluigi Tricoci, John H. Alexander, Samuel D. Wright, Charles L. Shear	3
11	A multiple ascending dose study of CSL112, an infused formulation of ApoA‐I 2013 ·The Journal of Clinical Pharmacology ·Rachael Easton, Andreas Gille, Denise D’Andrea, Roslyn Davis, Samuel D. Wright, Charles L. Shear	74
12	Pharmacokinetics and Excretion of 14C-Bendamustine in Patients with Relapsed or Refractory Malignancy 2013 ·Drugs in R&D ·Anne-Charlotte Dubbelman, Hilde Rosing, Mona Darwish, Denise D’Andrea, Mary Lou Bond, Edward T. Hellriegel, Philmore Robertson, Jos H. Beijnen, Jan H.M. Schellens	27
13	Efficacy and tolerability of hydrocodone extended-release tablets for the treatment of moderate to severe pain in opioid-treated patients with osteoarthritis or low back pain 2012 ·Journal of Pain ·M. Hale, Denise D’Andrea, Rob Yang, Gwendolyn Niebler	0
14	An Open-Label Phase I Pharmacokinetic Study of [14c] Bendamustine in Patients with Relapsed or Refractory Malignancy 2011 ·Blood ·Anne-Charlotte Dubbelman, Hilde Rosing, Mona Darwish, Denise D’Andrea, Mary Bond, Edward T. Hellriegel, Jos H. Beijnen, Jan H.M. Schellens	1
15	Pharmacokinetics of armodafinil and modafinil after single and multiple doses in patients with excessive sleepiness associated with treated obstructive sleep apnea: A randomized, open-label, crossover study 2010 ·Clinical Therapeutics ·Mona Darwish, Mary Kirby, Denise D’Andrea, Ronghua Yang, Edward T. Hellriegel, Philmore Robertson	22
16	Bendamustine pharmacokinetic profile and exposure–response relationships in patients with indolent non-Hodgkin’s lymphoma 2010 ·Cancer Chemotherapy and Pharmacology ·Joel Owen, Murad Melhem, Julie Passarell, Denise D’Andrea, Mona Darwish, (unknown)	47
17	A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment 2009 ·Cancer Chemotherapy and Pharmacology ·Christopher J. Sweeney, Chris H. Takimoto, Leslie Wood, J. Porter, William Tracewell, Mona Darwish, Denise D’Andrea, Scot C. Remick	23
18	Structural Features of Nephritogenic Lupus Autoantibodies 1997 ·Methods ·(unknown), (unknown), Denise D’Andrea, Raghu Kalluri, Mary H. Foster, Michael P. Madaio	15
19	Lupus autoantibodies interact directly with distinct glomerular and vascular cell surface antigens 1996 ·Kidney International ·Denise D’Andrea, Brigitte Coupaye-Gerard, Thomas R. Kleyman, Mary H. Foster, Michael P. Madaio	75
20	Trimethoprim-Induced Hyperkalemia in a Patient with AIDS 1993 ·New England Journal of Medicine ·Michael Choi, Pedro C. Fernandez, (unknown), Brigitte Coupaye-Gerard, Denise D’Andrea, Harold M. Szerlip, Thomas R. Kleyman	83

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact